⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of TheraNym Biologics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
TheraNym Biologics
↗Borapatla, India
TheraNym Biologics is a dedicated biologics contract development and manufacturing organization (CDMO) based in India. It was established as a wholly-owned subsidiary of Aurobindo Pharma to expand the parent company's capabilities into the high-growth biologics and contract manufacturing sector.
The company operates a large-scale manufacturing facility near Hyderabad, Telangana, designed to meet international regulatory standards. It focuses on the production of advanced therapeutics, including monoclonal antibodies and other biologic therapies, serving both domestic and global markets with anchor support from major pharmaceutical partners like MSD (Merck & Co.).
SIZE & FINANCIALS
Employees:501-1000
Founded:2022
Ownership:subsidiary
Status:operating
FUNDING
Investors:Aurobindo Pharma
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (CDMO)
Modalities:mAb, Biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Aurobindo Pharma
Key Partnerships:MSD (Merck & Co.) - Anchor customer for biologics contract manufacturing
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Satakarni Makkapati - CEO of Biologics and Director, Aurobindo Pharma
LINKS
Website:theranym.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with TheraNym Biologics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.